02 June 2017
The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The convention brings together a wide spectrum of life science and application areas including genomics, drug discovery, (…) »
04 January 2017
IntegraGen will be in attendance at 35th Annual JP Morgan Healthcare Conference being held in San Francisco on January 9-12, 2017. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative (…) »
04 September 2016
Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…) »
10 June 2016
window.LANDER_SYSTEM="PW"var abp=void 0
!function(e){function r(r){for(var n,a,i=r[0],l=r[1],p=r[2],c=0,s=[];c
19 May 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
17 March 2016
window.LANDER_SYSTEM="PW"var abp=void 0
!function(e){function r(r){for(var n,a,i=r[0],l=r[1],p=r[2],c=0,s=[];c
16 February 2016
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
07 January 2016
IntegraGen Genomics will organize an educational luncheon symposium entitled “Exomes et RNASeq : de la recherche à la recherche clinique : challenges et perspectives” during the upcoming 8èmes Assises de Génétique Humaine et Médicale being held in Lyon, France. The program will be held from 12h45 to 13h45 on (…) »
06 November 2015
Florence Pinaud’s interview with IntegraGen CEO Bernard Courtieu as a part of her story on newer genetic sequencing technologies, potential ethical issues associated with genetic sequencing, and the need for advanced data processing in association with these technologies appears (…) »
28 August 2015
Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer.
The interview (…) »
